沙利度胺联合复方斑蝥胶囊治疗进展期肝细胞癌的初步研究  

The efficacy and safety of thalidomide in combination with compound cantharidin capsules for patients with advanced hepatocellular carcinoma

作　　者：洪艳艳[1] 闫敏[1] 许苗苗[1] 惠锦林[1] 

机构地区：[1]安徽医科大学第二附属医院肿瘤中心,合肥230601

出　　处：《安徽医学》2011年第12期1987-1989,共3页Anhui Medical Journal

摘　　要：目的评价沙利度胺联合复方斑蝥胶囊治疗进展期肝细胞癌的疗效及不良反应。方法沙利度胺(第1周100 mg/d,第2周起200 mg/d)联合复方斑蝥胶囊治疗(3粒/次,2次/d)直至疾病进展、死亡或出现不能耐受的副反应。结果 12例患者接受治疗,无完全缓解(CR)和部分缓解(PR)患者,疾病稳定(SD)5例(41.7%),疾病进展(PD)7例(58.3%),疾病控制率(DCR)41.7%;无进展生存(PFS)1.3～4.3个月,中位PFS为2个月;总生存(OS)2～6.7个月,中位OS为5.5个月。患者的KPS评分、睡眠、食欲、体质量、情绪等得到改善。最常见的不良反应为乏力和嗜睡。结论沙利度胺联合复方斑蝥胶囊治疗进展期肝细胞癌有一定疗效,并能改善患者的生活质量,且耐受性好、治疗费用低、用药方便,值得进一步扩大病例数开展临床研究。Objective To evaluate the efficacy and safety of thalidomide in combination with compound cantharidin capsules for patients with advanced hepatocellular carcinoma （HCC）. Methods Advanced hepatocel｜ular carcinoma was defined as either metastatic or not amenable to surgical or loeoregional therapies. Diagnosis of HCC was based on clinical or pathological grounds. Patients received thalidomide （100 mg/ d in the first week, and than 200 mg/ d） and compound eantharidin capsules （3 pills bid） until unaecepted toxicity, tumor progression occurred, or death, with efficacy measured at the end of the second month. Results Twelve patients received the treatment. Stable disease （SD） was found in 5 patients （41.7 %）. Disease control rate （DCR） was 41.7 %. The median progression-free survival （PFS） and overall survival were 2 months and 5.5 months, respectively. OS at 6 months was 41.7 %. The commonest toxieities included grade 1-2 fatigue and lethargy, with the rates of 66.7 % and 55.8 %, with no grade 3 or 4 toxicities and treatment-related deaths. Conclusions The combination regimen of thalidomide and compound cantharidin capsules is effective, well tolerated, low cost and easy to take for patients with advanced hepatocellular carcinoma. It is worthy of further study.

关 键 词：癌 肝细胞性 沙利度胺 斑蝥素 药物疗法 

分 类 号：R735.7[医药卫生—肿瘤]